Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 7:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 60 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adult Subject Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Observe Safety And Blood Concentrations Of PF-04995274 During And Following the Administration of Multiple Doses Of PF-04995274 In Healthy Adult And Healthy Elderly Volunteers.

NCT01169714
View directory record Official record
Conditions
Healthy
Interventions
0.1 mg PF-04995274, 1 mg PF-04995274, 10 mg PF-04995274, 15 mg PF-04995274, 1.0 mg PF-04995274
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2011 · Synced Sep 5, 2026, 7:19 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia

NCT02961218
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
ACZ885, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
8 Years to 20 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Atlanta, Georgia • Augusta, Georgia • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 5, 2026, 7:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of The Safety And Pharmacokinetics Of CE-326,597 In Patients With Asymptomatic Gallstones

NCT00576589
View directory record Official record
Conditions
Obesity
Interventions
CE-326,597, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
12
States / cities
Anniston, Alabama • Phoenix, Arizona • Anaheim, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2010 · Synced Sep 5, 2026, 7:19 AM EDT
Completed Phase 1Phase 2 Interventional

Acute Nicotine Gum and Tinnitus Loudness in Non-Smoking Adults

NCT07772089
View directory record Official record
Conditions
Tinnitus, Chronic Subjective Tinnitus
Interventions
Nicotine polacrilex gum 4 mg, Placebo gum
Drug · Other
Lead sponsor
San Diego State University
Other
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 5, 2026, 7:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Bioavailability and Food Effect of SACT-1 and Edurant® Tablets in Healthy Adult Volunteers

NCT05358756
View directory record Official record
Conditions
Healthy Subject
Interventions
SACT-1, EDURANT 25Mg Tablet
Drug
Lead sponsor
Aptorum International Limited
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Sep 5, 2026, 7:19 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Safety and Effectiveness of NOA VOLUME Injectable Gel in Adult Participants Compared to JUVÉDERM VOLUMA XC for Improvement of Mid-Face Volume

NCT06734351
View directory record Official record
Conditions
Mid Face Volume Deficit
Interventions
NOA VOLUME, VOLUMA XC
Device
Lead sponsor
AbbVie
Industry
Eligibility
22 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
15
States / cities
Birmingham, Alabama • Glendale, Arizona • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 5, 2026, 7:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

4-way Crossover QT Evaluation in Healthy Subjects

NCT03709927
View directory record Official record
Conditions
Cardiac Repolarization in Healthy Subjects
Interventions
ZTI-01, Moxifloxacin 400mg, Placebo IV
Drug · Other
Lead sponsor
Nabriva Therapeutics AG
Industry
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Sep 5, 2026, 7:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults

NCT01892189
View directory record Official record
Conditions
Ketamine-Induced Brain Activity Changes, Psychotic-like Symptoms
Interventions
Ketamine, TAK-063, TAK-063 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 5, 2026, 7:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Super-Oxygenated Water on Blood Oxygen Saturation

NCT07016191
View directory record Official record
Conditions
Adult Subject
Interventions
Ingestion of Water
Other
Lead sponsor
Inhale, Inc
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Westlake Village, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 5, 2026, 7:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Evaluating the Absorption Of Varenicline Through The Skin Following Once Daily Application Of A Patch For 14 Days

NCT01234142
View directory record Official record
Conditions
Smoking Cessation
Interventions
varenicline free base patch, placebo patch
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Oct 13, 2011 · Synced Sep 5, 2026, 7:19 AM EDT
Completed Phase 4 Interventional

Naturalistic Substitution of Concerta in Adult Subject With ADHD Receiving Immediate Release Methylphenidate

NCT00302406
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
methylphenidate hydrochloride, OROS methylphenidate hydrochloride (CONCERTA)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2011 · Synced Sep 5, 2026, 7:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Irritation and Sensitization Study of HP-5000 Topical System

NCT04882319
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
HP-5000 Topical Patch, HP-5000 Placebo Patch, Saline Patch
Drug
Lead sponsor
Noven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Sep 5, 2026, 7:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Observe Safety And Concentrations Of PF-05297909 And Proteins In Both Blood And Cerebrospinal Fluid After A Single Dose Of PF-05297909 In Healthy Adults

NCT01462851
View directory record Official record
Conditions
Healthy
Interventions
PF-05297909 25 mg, PF-05297909 100 mg, PF-05297909 250 mg, PF-05297909 525 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Glendale, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 12, 2012 · Synced Sep 5, 2026, 7:19 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults

NCT02079168
View directory record Official record
Conditions
Keloid
Interventions
RXI-109, Placebo
Drug
Lead sponsor
RXi Pharmaceuticals, Corp.
Industry
Eligibility
21 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Miami, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 13, 2016 · Synced Sep 5, 2026, 7:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple-Dose PK Study to Evaluate the Comparative Bioavailability of PrimeC Tablets to Ciprofloxacin Tablets Co-administered With Celecoxib Capsules, in Healthy Adult Subject

NCT05436678
View directory record Official record
Conditions
Pharmacokinetics
Interventions
PrimeC 748 mg, Ciprofloxacin 750 MG, Celecoxib 200mg
Drug
Lead sponsor
NeuroSense Therapeutics Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 5, 2026, 7:19 AM EDT
Completed Phase 2 Interventional

A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight

NCT00542009
View directory record Official record
Conditions
Weight Management, Treatment Of Obesity
Interventions
CE-326,597 100 mg QD, CE-326,597 50 mg QD, CE-326,597 25 mg QD, Placebo, CE-326,597 5mg QD
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
30
States / cities
Phoenix, Arizona • Fresno, California • National City, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Sep 5, 2026, 7:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study of the Pharmacokinetic Variability and Relative Bioavailability of the Phase 3 and Common Blend Formulations of Eliglustat in Healthy Adult Subjects

NCT01452542
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Eliglustat, common blend proposed commercial formulation, Eliglustat, Phase 3 capsule formulation
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2015 · Synced Sep 5, 2026, 7:19 AM EDT
Completed Phase 3 Interventional Results available

Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy

NCT02012218
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
ADT, Brexpiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
24
States / cities
Garden Grove, California • Temecula, California • Orlando, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2015 · Synced Sep 5, 2026, 7:19 AM EDT
Recruiting No phase listed Observational

AeviceMD for Detection of Wheeze in Pediatric and Adult Populations

NCT06691971
View directory record Official record
Conditions
Subject Presenting Wheeze, Asthma, Bronchial Disease, Respiratory Tract Diseases, Pediatric Asthma, Chronic Respiratory Disease
Interventions
AeviceMD
Device
Lead sponsor
Aevice Health Pte. Ltd.
Other
Eligibility
3 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Sep 5, 2026, 7:19 AM EDT
Completed Phase 2 Interventional Results available

Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients

NCT03610724
View directory record Official record
Conditions
Non-Hodgkin Lymphoma
Interventions
Tisagenlecleucel, lymphodepleting chemotherapy, Bridging Therapy
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Up to 25 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Sep 5, 2026, 7:19 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Hezkue®, Hezkue Turbo®, and Commercial Sildenafil Products in Fed Healthy Male Subject

NCT07117383
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
ASP-001.1, ASP-001, Commercial Sildenafil and Sildenafil/Tadalafil Products
Device · Drug
Lead sponsor
Aspargo Labs, Inc
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Sep 5, 2026, 7:19 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of PF-05180999 In Healthy Adults

NCT01981499
View directory record Official record
Conditions
Migraine
Interventions
PF-05180999, Placebo, 120 mg MR PF-05180999, 360 mg MR PF-05180999, 10 mg cetirizine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Sep 5, 2026, 7:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Human Mass Balance Study of HMS5552 in Healthy Subjects

NCT03158506
View directory record Official record
Conditions
Healthy Subject
Interventions
HMS5552
Drug
Lead sponsor
Hua Medicine Limited
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 30, 2018 · Synced Sep 5, 2026, 7:19 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery in Healthy Adults

NCT02030275
View directory record Official record
Conditions
Hypertrophic Scar
Interventions
RXI-109, Placebo
Drug
Lead sponsor
RXi Pharmaceuticals, Corp.
Industry
Eligibility
21 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
4
States / cities
Lake Worth, Florida • Chicago, Illinois • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2016 · Synced Sep 5, 2026, 7:19 AM EDT